PKC signaling in glioblastoma.
Glioblastoma Multiforme (GBM) is the most aggressive brain tumor characterized by intratumoral heterogeneity at cytopathological, genomic and transcriptional levels. Despite the efforts to develop new therapeutic strategies the median survival of GBM patients is 12-14 months. Results from large-scale gene expression profile studies confirmed that the genetic alterations in GBM affect pathways controlling cell cycle progression, cellular proliferation and survival and invasion ability, which may explain the difficulty to treat GBM patients. One of the signaling pathways that contribute to the aggressive behavior of glioma cells is the protein kinase C (PKC) pathway. PKC is a family of serine/threonine-specific protein kinases organized into three groups according the activating domains. Due to the variability of actions controlled by PKC isoforms, its contribution to the development of GBM is poorly understood. This review intends to highlight the contribution of PKC isoforms to proliferation, survival and invasive ability of glioma cells.
Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. analiacarmo@gmail.com
Anália
A
do Carmo
Joana
J
Balça-Silva
Diana
D
Matias
Maria Celeste
MC
Lopes
D000818:Animals; D001932:Brain Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005909:Glioblastoma / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D011493:Protein Kinase C / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
D011493:Protein Kinase C
glioblastoma multiforme (GBM); glioma; protein kinase C (PKC); signaling pathway; temozolomide (TMZ)